Immunotherapies

Peer Reviewed Paper: Novel Immunotherapy Actives CD4 Helper T Cells using HLA-Class II Molecules

The findings detailed in an upcoming peer-reviewed paper provide a rationale for the encouraging clinical results observed with Bria-IMT™, an immunotherapy from BriaCell Therapeutics, in current and past clinical testing.  The paper will appear in Frontiers in Immunology, the 5th most cited journal in Immunology worldwide.  Bria-IMT™, also known as SV-BR-1-GM, has caused remarkable reduction […]

cancer Cancer Discovery

Early Evidence of Efficacy and Safety Seen in Novel Targeted Immunotherapy

An immune-oncology focused biotechnology company, BriaCell, has provided a clinical update on its lead immunotherapy drug for advanced breast cancer. BriaCell provided further update on its ongoing clinical trial of Bria-IMT™ according to Protocol WRI-GEV-007 (listed in ClinicalTrials.gov as NCT03066947).  Six patients have received inoculations since the trial began in early 2017, with the observation […]

Cancer Discovery

BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer

BriaCell, an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, has provided a clinical update regarding its ongoing clinical trials of Bria-IMT™ (formerly referred to as SV-BR-1-GM). BriaCell currently is enrolling patients in two separate but related clinical trials. Trial WRI-GEV-007 (listed in ClinicalTrials.gov as NCT03066947) is a Phase I/IIa clinical study designed […]